Preclinical findings predicting efficacy and side‐effect profile of LY 2940094, an antagonist of nociceptin receptors

• Published in: Pharmacology research & perspectives 2016-12, Vol.4 (6)
• Main Authors: Witkin, Jeffrey M., Rorick‐Kehn, Linda M., Benvenga, Mark J., Adams, Benjamin L., Gleason, Scott D., Knitowski, Karen M., Li, Xia, Chaney, Steven, Falcone, Julie F., Smith, Janice W., Foss, Julie, Lloyd, Kirsti, Catlow, John T., McKinzie, David L., Svensson, Kjell A., Barth, Vanessa N., Toledo, Miguel A., Diaz, Nuria, Lafuente, Celia, Jiménez, Alma, Benito, Alfonso, Pedregal, Conception, Martínez‐Grau, Maria A., Post, Anke, Ansonoff, Michael A., Pintar, John E., Statnick, Michael A.
• Format: Article
• Language: English
• Subjects: Antidepressants; Bioavailability; Drug dosages; Experiments; Hypotheses; Laboratories; Mental depression; Neurosciences; Pharmacology; Serotonin
• ISSN: 2052-1707; 2052-1707
• DOI: 10.1002/prp2.275

Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide whose receptor is designated ORL1 or nociceptin receptor (NOP). We utilized a potent, selective, and orally bioavailable antagonist with documented engagement with NOP receptors in vivo to assess antidepressant‐ and anxiolytic‐related pharmacological effects of NOP receptor blockade along with measures of cognitive and motor impingement. LY2940094 ([2‐[4‐[(2‐chloro‐4,4‐difluoro‐spiro[5H‐thieno[2,3‐c]pyran‐7,4′‐piperidine]‐1′‐yl)methyl]‐3‐methyl‐pyrazol‐1‐yl]‐3‐pyridyl]methanol) displayed antidepressant‐like behavioral effects in the forced‐swim test in mice, an effect absent in NOP−/− mice. LY2940094 also augmented the behavioral effect of fluoxetine without changing target occupancies (NOP and serotonin reuptake transporter [SERT]). LY2940094 did not have effects under a differential‐reinforcement of low rate schedule. Although anxiolytic‐like effects were not observed in some animal models (conditioned suppression, 4‐plate test, novelty‐suppressed feeding), LY2940094 had effects like that of anxiolytic drugs in three assays: fear‐conditioned freezing in mice, stress‐induced increases in cerebellar cGMP in mice, and stress‐induced hyperthermia in rats. These are the first reports of anxiolytic‐like activity with a systemically viable NOP receptor antagonist. LY2940094 did not disrupt performance in either a 5‐choice serial reaction time or delayed matching‐to‐position assay. LY2940094 was also not an activator or suppressor of locomotion in rodents nor did it induce failures of rotarod performance. These data suggest that LY2940094 has unique antidepressant‐ and anxiolytic‐related pharmacological effects in rodents. Clinical proof of concept data on this molecule in depressed patients have been reported elsewhere.